enGene

enGene, a biotechnology company, develops a mucosal immunotherapy platform for the treatment of inflammatory bowel disease and diabetes.

enGene Inc., based in Vancouver, BC, has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others